Herceptin Hylecta™ (trastuzumab/hyaluronidase-oysk) – New formulation approval
February 28, 2019 - Genentech announced the FDA approval of Herceptin Hylecta (trastuzumab/hyaluronidase-oysk) subcutaneous (SC) injection, in adults for the treatment of HER2-overexpressing breast cancer as follows:
Download PDF
